Literature DB >> 18629828

Improvement of recombinant protein production with the human adenovirus/293S expression system using fed-batch strategies.

I Nadeau1, A Garnier, J Côté, B Massie, C Chavarie, A Kamen.   

Abstract

The human adenovirus/293S cell expression system is used for the production of either recombinant protein or adenovirus vectors for use in gene therapy. In this work, the production of protein tyrosine phosphatase (PTP1C) was used as a model for the scale-up of both applications. Maximum specific production of 30 to 45 mug of active protein/10(6) cells was maintained upon infection with adenovirus vectors at cell densities between 2 x 10(6) to 3 x 10(6) cells/mL in a 3.5-L bioreactor. This was achieved by resuspending the culture in fresh medium at infection time. The pH was kept at 7.0 throughout the experiment and, at 24 h postinfection, glucose and essential amino acids were added. Attempts to replace the complete change of medium at the time of infection with nutrient supplementation of the used medium led to lower production levels, suggesting that protein expression was limited not by the absence of a key nutrient but by inhibitory factors. Two potentially inhibitory factors were investigated: lactic acid accumulation and increased osmolarity. Medium acidification such as that which would be brought about by lactic acid accumulation was shown to depress PTP1C production. The lactate molecule itself decreased the cell viability when added in concentrations of 20 mM or more. But the specific productivity was affected at higher lactate concentrations of 40 mM or more. Additions of glucose, amino acids, and NaHCO(3) used to control pH, led to increases in osmolarity. Osmolarities above 400 mOsm lowered cell density. However, specific production was not significantly affected below 500 mOsm. But, at 500 mOsm, PTP1C production peak was shifted from 48 to 72 hpi. Because of the cell loss, this per cell yield increase did not translate into higher volumetric production. When glucose concentrations was kept at 5 mM by fed-batch addition, lactate production and increases in osmolarity were reduced. In shake flasks, this method permitted maximum production with cells resuspended either in fresh or spent medium at infection. This fed-batch process was implemented successfully at the 3.5-L scale. Fed-batch with glucose may provide a means to increase infected-cell density beyond 3 x 10(6) cells/mL.

Entities:  

Year:  1996        PMID: 18629828     DOI: 10.1002/(SICI)1097-0290(19960920)51:6<613::AID-BIT1>3.0.CO;2-K

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  7 in total

1.  Cell culture processes for the production of viral vectors for gene therapy purposes.

Authors:  James N Warnock; Otto-Wilhelm Merten; Mohamed Al-Rubeai
Journal:  Cytotechnology       Date:  2006-06-30       Impact factor: 2.058

2.  A high-yielding serum-free, suspension cell culture process to manufacture recombinant adenoviral vectors for gene therapy.

Authors:  G Schoofs; T J Monica; J Ayala; J Horwitz; T Montgomery; G Roth; F J Castillo
Journal:  Cytotechnology       Date:  1998-11       Impact factor: 2.058

3.  XIAP gene expression protects β-cells and human islets from apoptotic cell death.

Authors:  Hao Wu; Ravikiran Panakanti; Feng Li; Ram I Mahato
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

4.  Development and improvement of a serum-free suspension process for the production of recombinant adenoviral vectors using HEK293 cells.

Authors:  Y S Tsao; R Condon; E Schaefer; P Lio; Z Liu
Journal:  Cytotechnology       Date:  2001-11       Impact factor: 2.058

5.  Comparison of manufacturing techniques for adenovirus production.

Authors:  P Iyer; J M Ostrove; D Vacante
Journal:  Cytotechnology       Date:  1999-07       Impact factor: 2.058

6.  Metabolic and kinetic analyses of influenza production in perfusion HEK293 cell culture.

Authors:  Emma Petiot; Danielle Jacob; Stephane Lanthier; Verena Lohr; Sven Ansorge; Amine A Kamen
Journal:  BMC Biotechnol       Date:  2011-09-01       Impact factor: 2.563

Review 7.  Use of adenoviral vectors as veterinary vaccines.

Authors:  T B Ferreira; P M Alves; J G Aunins; M J T Carrondo
Journal:  Gene Ther       Date:  2005-10       Impact factor: 5.250

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.